Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.48 USD
Change Today -0.58 / -3.40%
Volume 137.0K
BLCM On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

bellicum pharmaceuticals inc (BLCM) Snapshot

Open
$16.65
Previous Close
$17.06
Day High
$17.18
Day Low
$16.36
52 Week High
01/12/15 - $33.63
52 Week Low
08/24/15 - $15.05
Market Cap
436.6M
Average Volume 10 Days
351.2K
EPS TTM
$-22.84
Shares Outstanding
26.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BELLICUM PHARMACEUTICALS INC (BLCM)

Related News

No related news articles were found.

bellicum pharmaceuticals inc (BLCM) Related Businessweek News

No Related Businessweek News Found

bellicum pharmaceuticals inc (BLCM) Details

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. The company’s preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

35 Employees
Last Reported Date: 03/20/15
Founded in 2004

bellicum pharmaceuticals inc (BLCM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $373.7K
Co-Founder, Chief Technology Officer and Dire...
Total Annual Compensation: $259.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $367.1K
Compensation as of Fiscal Year 2014.

bellicum pharmaceuticals inc (BLCM) Key Developments

Bellicum Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Bellicum Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported grant revenues of $84,000 against $554,000 a year ago. Operating loss was $10,705,000 against $3,273,000 a year ago. Net loss was $10,534,000 against $3,281,000 a year ago. Net loss attributable to common shareholders was $10,534,000 or $0.40 per share basic and diluted against $3,845,000 or $1.81 per share basic and diluted a year ago. For the six months, the company reported grant revenues of $191,000 against $1,106,000 a year ago. Operating loss was $18,513,000 against $5,550,000 a year ago. Net loss was $18,292,000 against $6,675,000 a year ago. Net loss attributable to common shareholders was $18,292,000 or $0.70 per share basic and diluted against $6,675,000 or $3.35 per share basic and diluted a year ago.

Bellicum Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 13, 2015

Bellicum Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 13, 2015

Bellicum Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 13, 2015

Bellicum Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLCM:US $16.48 USD -0.58

BLCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLCM.
View Industry Companies
 

Industry Analysis

BLCM

Industry Average

Valuation BLCM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 517.8x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 384.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BELLICUM PHARMACEUTICALS INC, please visit www.bellicum.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.